A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：HUMAN GENE THERAPY ISSN： 1043-0342 版本： SCI-CDE 出版频率： Monthly 出版社： MARY ANN LIEBERT, INC, 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, USA, NY, 10801   出版社网址： http://www.liebertpub.com/ 期刊网址： http://www.liebertpub.com/products/product.aspx?pid=19 影响因子： 5.695 主题范畴： BIOTECHNOLOGY & APPLIED MICROBIOLOGY;    GENETICS & HEREDITY;    MEDICINE, RESEARCH & EXPERIMENTAL 变更情况： The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product test 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal A rapid-publication peer-reviewed journal covering all aspects of human gene therapy. Publishes scientific papers on original investigations into the transfer and expression of genes in mammals, including humans. Improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, are covered. Includes ethical/legal/regulatory papers related directly to the area of gene transfer into humans. Indexed/Abstracted in: MEDLINE; Current Contents®/Life Sciences; EMBASE/Excerpta Medica; Science Citation Index Expanded; Science Citation Index®; BIOSIS Previews; Biotechnology Citation Index®; Biological Abstracts; EMBiology; Scopus Instructions to Authors http://mc.manuscriptcentral.com/hum Please read all the instructions to authors before submitting. To help defray the cost of printing, the Publisher requests that page charges of $75 per printed page be paid by all authors who have funds available from research grants or from their institutions. It should be noted that ability to pay page charges is not a prerequisite for publication in the Journal.   Manuscript Submission and Copyright Agreement Form The Copyright Agreement form (available from web site at transfer_of_copyright.pdf) should be submitted once your paper has been accepted for publication.  Manuscripts cannot be published without this form. The corresponding author is responsible for obtaining signatures of coauthors. Authors not permitted to release copyright must still return the form signed under the statement of the reason for not releasing the copyright.  Upon acceptance of your paper, please fax the Copyright Agreement form to 215-494-5443. Papers must be submitted via upload in a word processing format, preferably in Microsoft Word. Please do not include artwork within the text document. Figures and tables should be supplied in separate files, be labeled clearly, and should be in TIFF or EPS formats. Please see the Tables and Illustrations section for further details on art submission. On the first page, give the title of the paper, name(s) of author(s), institutional affiliation(s), and the name (with complete address and phone number) to whom correspondence should be directed; supply a running title of 40 characters including spaces. On the second page, supply an abstract of no more than 250 words, stating the aims, results, and conclusions drawn from the study.  This should be followed by the introduction, materials and methods, results, discussion, acknowledgments, and references. Results and discussion may either be separate sections or combined. Begin each of these sections on a separate page. Authors should review the style and clarity of their manuscripts with colleagues before submission. Please follow the protocol described herein to avoid delay in publication. Authors should note that manuscripts may be edited if needed to ensure clear grammatic English usage. The editors welcome suggestions concerning potential reviewers. Brief Report Submission of Brief Reports is also welcome. A Brief Report should communicate new methodological information in the field of gene transfer and therapy. It should be divided as follows: Summary (no more than 250 words), Introduction, Materials and Methods, Results and Discussion (please consider that in Brief Reports, Results and Discussion can be fused), Acknowledgments, and References.  The whole report should be composed of no more than four journal pages (about 3,000 words), including tables and figures. For general rules please follow the guidelines given for regular papers. Tables and Illustrations Use Arabic numerals to number tables. Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences. Provide titles for all tables. Define all acronyms in table footnotes. All other types of table footnotes should be designated using superscript letters, not symbols. Electronic submission of art MUST follow these guidelines: Do not include any illustrations as part of your text file. Do not prepare any figures in Word as they are not workable. Line illustrations must be submitted at 1200 DPI. Halftones and color photos should be submitted at 300 DPI. Please submit only TIFF or EPS files. Color art must be saved as CYMK not RGB or INDEX. If RGB files are submitted, the files will be converted to CYMK, and some slight color variation may occur. Do NOT submit PowerPoint or Excel files. Adobe is the software of choice. A legend should be supplied for each illustration, and all legends numbered consecutively and provided (double spaced) on a separate page. All symbol definitions should be in figure legend, not as a key within the figure. If possible please use Arial font for figure text. Figures should be numbered in the order cited in the text.  Images should not show the name of the manufacturer. Please keep in mind that the figures will be reduced, so please do not submit large figures/graphs that contain small type, as the text within the figure will not be readable after reduction. The Journal will publish color photographs, but the author will be charged for the cost of color separations and printing at the rate of $275 per piece of color art plus $1,200 per page of color.  The Publisher will provide the author with a more precise cost estimate when the figures are received.  For further details, contact the Editor or Publisher.   Abstracts Each paper should have an abstract of no longer than 250 words. References All references in text should be cited alphabetically, within year, by authors and dates. e.g. The ribosomal RNA (rrn) operons in E. coli contain single copies of each of the 16S, 23S, and 5S r(RNA) genes (Pace, 1973; Rogers and Smith, 1973; Andrews et al., 1978). If more than two authors are involved, use et al. after the first author's name. e.g. (Sogin et al., 1971). If several papers by the same authors are cited in one sentence, use a lower case letter designation to indicate the individual papers. e.g. (Dunn and Studier, 1973a,b). Use same designation in reference list. All references in the reference section should be double spaced and listed in alphabetical order at the end of the paper. References should include complete titles of cited papers and all authors. Journal citation: PACE, N. (1973). Structure and synthesis of the ribosomal ribonucleic acid of prokaryotes. Bacteriol. Rev. 37, 562-603. Book citation: BROSIUS, J. (1987). Expression vectors employing A, trp, lac, and lpp-derived promoters. In Vectors, a Survey of Molecular Cloning Vectors and Their Uses. R.L. Rodriguez and D.T. Denhardt, eds. (Butterworth Publishers, Stoneham, MA) pp. 205-225. When dates from an unpublished source are given, supply the researcher's name. If work is in press, give journal in which it is to be published or name of publisher. Abbreviations of journal names should follow the style of Medline. Permissions The author must obtain permission whenever it is required in conjunction with the reproduction of material such as figures and tables from copyrighted material. Written permission must be obtained from the publisher of the journal or book concerned. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table, or of the legend of a reprinted figure should read, "reprinted by permission from Jones et al." and list the appropriate reference. All permissions listings must be shown in the manuscript—they cannot be entered on proofs. Manuscripts submitted to this Journal must not be under consideration elsewhere.  Acknowledgements Any contributor who does not meet the criteria for authorship should be listed in the “Acknowledgements” section.  Examples of a contributor may be individuals who provided technical support, writing assistance, or provided research materials.  All funding sources, institutional and corporate, should be listed in this section. Author Disclosure Statement  Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist."   Definitions Competing Interests:  A competing interest exists when an individual (or the individual’s institution) has financial or personal relationships that inappropriately influence his actions.  These competing interests may be potential or actual, financial or other.  Competing Financial Interests:  Personal Financial Interests:  Stocks or shares in a company that may gain or lose financially from publication of this paper; consulting fees or other remuneration from an organization that may gain or lose financially from publication of this paper; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of this paper.    Funding: Research support by organizations that may gain or lose financially from publication of this paper.  This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.   Employment:  Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of this paper.    Other Competing Interests:  Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment. Competing Interest for Reviewers   The Editors leave it to the discretion of the invited reviewer to state whether or not they have any type of conflict with any of the authors on the manuscript.  Such conflicts might include:  recent or ongoing collaborations with the authors, having previously reviewed the manuscript in its draft stages, reviewer is in direct competition with the authors, or has a financial interest in the outcome of the manuscript.  Editors will take this information into consideration when deciding whether or not to use the reviewer, or in evaluation of the reviewer’s comments.    Should the reviewer feel they can not be objective in their review for financial, personal or other reasons, they should decline to review the manuscript.    We do not exclude reviewers who previously reviewed a specific manuscript for another journal.  The comments offered by a qualified reviewer are valuable to the peer-review process and it is important for the reviewer to consider that the author may have already revised the manuscript based on his/her previous comments.  Competing Interest for Editor-in-Chief and Associate Editors   The Editor-in-Chief and Associate Editors will rescue themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest. Sharing of Materials Policy   Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings.    Reprints Reprints may be ordered by using the special reprint order form that will accompany the proofs. Reprints ordered after the issue is printed will be charged at a higher rate.   Human Gene Therapy will distribute or make available short press releases on newsworthy papers.   Publisher The Journal is published monthly by Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801-5215.  Telephone: (914) 740–2100; fax: (914) 740–2108. var links = document.getElementsByName("linkLargerCover"); for(var i=0; i'); w.document.write(' '); w.document.write(' '); w.document.close(); }     Editorial Board Editor-in-Chief James M. Wilson, MD, PhD University of Pennsylvania School of Medicine Gene Therapy Program Department of Pathology and Laboratory Medicine Suite 2000, Translational Research Laboratories 125 S. 31st Street Philadelphia, PA 19104-3403 Tel: (215) 898-0819 Fax: (215) 898-6588 wilsonjm@mail.med.upenn.edu Deputy Editor Bernd Gansbacher, MD, PhD Institut für Experimentelle Onkologie und Therapieforschung Technische Universität München Ismaniger Str. 22 81675 Munich, Germany Tel: 49-89-41404450 Fax: 49-89-41404476 bernd.gansbacher@lrz.tum.de Associate Editors Kenneth I. Berns, MD, PhD UF Genetics Institute Dept. of Molecular Genetics and Microbiology College of Medicine Cancer/Genetics Research Complex 1376 Mowry Road, Room 115 Gainesville, FL 32610-3610 Tel: (352) 273-8100 Fax: (352) 273-8284 kberns@ufl.edu Fatima Bosch, PhD Center of Animal Biotechnology and Gene Therapy Universitat Autònoma de Barcelona Edifici H 08193-Bellaterra, Spain Tel:   34-93-581-4179 Fax: 34-93-581-4180 fatima.bosch@uab.es Mark A. Kay, MD, PhD Departments of Pediatrics and Genetics Stanford University School of Medicine 300 Pasteur Drive, Room G305 Stanford, CA 94305 Tel:  (650) 498-6531 Fax: (650) 498-6540 markay@stanford.edu Luigi Naldini, MD, PhD HSR-TIGET San Raffaele Telethon Institute for Gene Therapy via Olgettina 58 20132 Milano, Italy Tel:  39-02-2643-4703/4875 Fax: 39-02-2643-4688 naldini.luigi@hsr.it Yu-quan Wei, M.D., PhD National Key Laboratory of Biotherapy and Cancer Center West China Hospital, West China Medical School, Sichuan University Gaopeng Street, Keyuan Street Road 4, No. 1 Chengdu, Sichuan 610041 P.R. China Ph 86-28-85164059 Fax 86-28-85164060 E-mail: yuquawei@vip.sina.com; yuquawei@hotmail.com  Scientific Editorial Board Kari Airenne, PhD University of Eastern Finland Ramon Alemany, PhD Institut Català d´Oncologia-IDIBELL Ian E. Alexander, MBBS, PhD University of Sydney Daniel G. Anderson, PhD Massachusetts Institute of Technology Christopher Baum, MD, PhD Hannover Medical School, FRG Chiara Bonini, MD San Raffaele Scientific Institute Xandra Breakefield, PhD Massachusetts General Hospital Juan A. Bueren, PhD CIEMAT Hildegard Büning, PhD University of Cologne Barrie J. Carter, PhD Carter BioConsulting Nathalie Cartier-Lacave, MD INSERM Toni Cathomen, PhD Hannover Medical School Saswati Chatterjee, PhD City of Hope National Medical Center June-Key Chung, MD, PhD Seoul National University Mary Collins, PhD Royal Free and University College Medical School Kenneth Cornetta, MD Indiana University School of Medicine François-Loïc Cosset, PhD Ecole Normale Supérieure de Lyon Gay M. Crooks, MB, BS University of California, Los Angeles Ronald G. Crystal, MD Weill Cornell Medical College   George Dickson, PhD Royal Holloway - University of London    Anja Ehrhardt, PhD University of Munich John Engelhardt, PhD University of Iowa Erik Falck-Pedersen, PhD Weill Cornell Medical College  Sarah Ferber, PhD Sheba Medical Center Terence R.  Flotte, PhD University of Massachusetts Medical School Anne Galy, PhD GENETHON Guangping Gao, PhD University of Massachusetts Medical School Manuel Grez, PhD University of Frankfurt Yajun Guo, MD, PhD Shanghai Second Military Medical University Akseli Hemminki, MD University of Helsinki Ulrich R. Hengge, MD Heinrich-Heine-University Roland W. Herzog, PhD University of Florida Steven Howe, PhD UCL Institute of Child Health Wenlin Huang, PhD, MD SunYat-sen University Carl June, MD University of Pennsylvania School of Medicine Chang-Yuil Kang, PhD Seoul National University Hans-Peter Kiem, MD University of Washington School of Medicine David Klatzmann, MD, PhD INSERM Robert Kotin, PhD National Heart, Lung, and Blood Institute Francois M. Lemoine, MD, PhD Université Pierre and Marie Curie You Lu, MD Sichuan University Patrick Midoux, PhD INSERM - CNRS Philippe Moullier, MD, PhD INSERM Genthon Rita Mulherkar, PhD Tata Memorial Centre   Nicholas Muzyczka, PhD University of Florida Hiroyuki Nakai, MD, PhD University of Pittsburgh School of Medicine Timothy O’Brien, MD, PhD National University of Ireland, Galway  Richard Peluso, PhD Targeted Genetics Corporation Katherine Ponder, MD Washington University School of Medicine ZhiYong Qian, MD Sichuan University John E.J. Rasko, MBBS, PhD Centenary Institute and Royal Prince Alfred Hospital Paul D. Robbins, PhD University of Pittsburgh School of Medicine John J. Rossi, PhD City of Hope David W. Russell, MD, PhD University of Washington Steven J. Russell, MD, PhD Mayo Clinic College of Medicine Michel Sadelain, MD, PhD Memorial Sloan-Kettering Cancer Center Izumu Saito, MD University of Tokyo Debi P. Sarkar, PhD University of Delhi South Campus    Ton Schumacher, PhD The Netherlands Cancer Institute Arun Srivastava, PhD University of Florida College of Medicine George Stamatoyannopoulos, MD University of Washington Mark Tangney, PhD Cork Cancer Research Centre Adrian Thrasher, M.D., PhD UCL Institute of Child Health Victor W. van Beusechem, PhD VU University Medical Center Thierry Vanden Driessche, PhD University of Leuven Christof von Kalle, MD National Center for Tumor Diseases (NCT) Simon N. Waddington, PhD Imperial College of London Gerard Wagemaker, PhD Erasmus University Medical Center Matthew Weitzman, PhD Salk Institute John H. Wolfe, VMD, PhD University of Pennsylvania Jon A. Wolff, MD Roche Madison Inc Joseph C. Wu, MD, PhD Stanford University School of Medicine Xiao Xiao, PhD University of North Carolina  Rafael J. Yáñez-Muñoz, PhD Royal Holloway-University of London Yiping Yang, MD, PhD Duke University Medical Center Seppo Yla-Herttuala, MD, PhD University of Kuopio Yoshi Yonemitsu, MD, PhD Kyushu University Gideon Zamir, MD Hadassah-Hebrew University Medical Center Xia Zhao, MD Sichuan University  Editorial Office Scientific News Editors Sadik H. Kassim, PhD Luk H. Vandenberghe, PhD HGTnewswire@liebertpub.com Monique R. Molloy Editorial Manager Human Gene Therapy Suite 2000, Translational Research Laboratories 125 S. 31st Street Philadelphia, PA 19104-3403 Ph (215) 898-0819 Fax (215) 494-5443 HGT@mail.med.upenn.edu   Founding Editor W. French Anderson, MD